ГоловнаArchive of numbers2017Volume 25, issue 2 (91)The efficiency of betaferon in patients with uncertain prognosis in relapsing course of multiple sclerosis
Title of the article The efficiency of betaferon in patients with uncertain prognosis in relapsing course of multiple sclerosis
Authors Vasylovskyi Vitalii
Voloshyna Natalia
Negreba Tetiana
Tkachova Tetiana
Chernenko Maksym
In the section DIAGNOSTICS AND THERAPY OF NEUROLOGICAL DISORDERS
Year 2017 Issue Volume 25, issue 2 (91) Pages 5-11
Type of article Scientific article Index UDK 616.832-004.2-086.63-036-037-08 Index BBK -
Abstract We have examined the effi cacy, safety and tolerability of Betaferon in patients with uncertain prognosis in relapsing course of multiple sclerosis (MS). We had performed the evaluation of clinical and radiological effi cacy in 30 patients before the course of treatment, in 24 patients after 12 months period against the background of the treatment, and after 24 months immediately after the course of treatment. We have been considering the frequency and severity of relapses, the dynamics of neurological impairment according to the Expanded Disability Status Score (EDSS) scale and the Kurtzke Expanded Disability Status Scale; Magnetic resonance imaging (MRI) data, obtained before and after the 24-month period of treatment. According the results of our examination, we have developed the criteria of high, moderate and low treatment effi cacy. The high effi cacy was obtained in 33.3 % of patients by the end of Betaferon course. The moderate effi cacy had been defi ned in 29.2 % of patients. The low effi cacy had been defi ned in 16.7 % of patients. We have observed the state stabilization 12.5 % of patients with the absence of clinical and radiological dynamics. We determined the lack of effi cacy in 8.3 % of patients. We have proved the clinical and radiological effi cacy of Betaferon as a fi rst line drug, which modifies the aggressive relapsing course of MS in patients with uncertain prognosis. A signifi cant decrease in the average frequency and severity of relapses, the tendency toward the decrease in the average score of disability, according to the EDSS and Kurtzke scales, combined with a decrease of active gadolinium-enhancing lesions on MRI, helped to extend the recurrent stage and reduced the risk of immediate transformation of relapsing course into the secondary-progressive course.
Key words multiple sclerosis, relapsing course, uncertain prognosis, clinical and radiological activity of disease, Betaferon, treatment effi cacy
Access to full text version of the article pdf download
Bibliography 1. Isaacs A., Lindenmann J. Virus interference. I. The interferon. // Proceedings of the Royal Society B: Biological Sciences. Published 12 September 1957; 146: 258—267. DOI: 10.1098/rspb.1957.0048.
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter randomized, doubleblind, placebo-controlled trial / The IFNB Multiple Sclerosis Study Group // Neurology. 1993. Vol. 43: № 4. P. 655—661. DOI: http:// dx.doi.org/10.1212/WNL.43.4.655 3. Paty D. W., Li D. K. Interferon beta-1b is eff ective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group // Ibid. P. 662—667.
4. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metaloproteinase-9 / [Stüve O., Dooley N. P., Uhm J. H. et al.] // Ann Neurol. 1996; 40(6): 853—863. 5. Interferon-beta in the treatment of multiple sclerosis: mechanisms of action / [Yong V. W., Chabot S., Stüve O., Williams G.] // Neurology. 1998. Vol. 51 (3). P. 682—689.
6. The effect of interferon-beta on blood brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis / [L. A. Stone, J. A. Frank, P. S. Albert et al.] // Ann neurol. 1995; 37(5): 611—619.
7. Шмидт Т. Е. Превентивная иммуномодулирующая терапия ремиттирующего рассеянного склероза // Неврологический журнал. 2006. Т. 11, № 1. С. 4—8.
8. Лечение рассеянного склероза Бетафероном / [Т. Л. Демина, Н. В. Хачанова, М. В. Давыдовская и др.] // Рассеянный склероз и другие демиелинизирующие заболевания. Москва : «Миклош», 2005. С. 417—428.
9. Ребиф 22 в лечении рассеянного склероза / [И. А. Завалишин, Е. И. Гусев, Н. Н. Яхно и др.] // Там же. С. 385—394.
10. Шмидт Т. Е., Яхно Н. Н. Рассеянный склероз. Москва : Медицина, 2003.
11. Boutros T., Croze E., Yong V. W. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes // J. Neurochem. 1997. Vol. 69 (3). P. 939—946.
12. Malik, O., Compston, A., Scolding, J. Interferon-beta inhibits mitogen induced astrocyte proliferation in vitro // J. Neuroimmunol. 1998. Vol. 86. P. 155—162.
13. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b / [S. Narayanan, N. De Stefano, G. Francis et al.] // J. Neurol. 2001. Vol. 248. P. 979—986.
14. Rieckman P., Maurer, M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis // Curr. Opin. Neurol. 2002. Vol. 15. P. 361—370.
15. Zeimssen T., Kumpfeld N., Klinkert W. Glatiramer acetatespecific T-helper 1- and 2-type cell lines produce BDNF: implication for multiple sclerosis therapy // Brain. 2002. Vol. 125. P. 2381—2391.
16. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time / [T. Kuhlmann, G. Lingfeld, A. Bitsch et al.] // Ibid. P. 2202—2212.
17. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” / [C. N. Polman, S. C. Reingold, G. Edan et al.] // Ann. Neurol. 2005. Vol. 58, № 6. Р. 840—846.
18. Прогностичні критерії при різних типах перебігу розсіяного склерозу / Н. П. Волошина, Т. В. Негреба, І. Л. Левченко, Т. М. Ткачова, О. В. Єгоркіна : Свідоцтво про реєстрацію авторського права на науковий твір № 39160 від 14.07.2011 р.